Notes
to the Financial Statements
September
30, 2018
(Unaudited)
The
results for the six months ended September 30, 2018 are not necessarily indicative of the results of operations for the full year.
These financial statements and related footnotes should be read in conjunction with the financial statements and footnotes thereto
included in the Company’s Annual Report on Form 10K for the year ended March 31, 2018, filed with the Securities and Exchange
Commission.
The
accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments
(which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and
cash flows at September 30, 2018 and for the related periods presented have been made.
NOTE
1 - ORGANIZATION AND BUSINESS OPERATIONS
Organization
and Description of Business
ALTAIR
INTERNATIONAL CORP. (the “Company”) was incorporated under the laws of the State of Nevada on December 20, 2012. The
Company’s physical address is 18934 N 92
nd
Way, Scottsdale, AZ 85255. The Company is in the development stage
as defined under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”)
915-205 "Development-Stage Entities.”
The
Company is currently engaged in identifying and assessing new business opportunities.
On
November 11, 2014, the Company entered into a strategic alliance with Cure Pharmaceutical Corporation (“CURE”), a
California company engaged in the development of oral thin film (“OTF”) for the delivery of nutraceutical, over-the-counter
and prescription products. This alliance was initially comprised of an Exclusive License and Distribution Agreement for CURE’s
Sildenafil Products in defined territories, a joint venture agreement for the procurement of equipment specific for oral thin
film products and further joint ventures and other business relationships for the purpose of completing the development and marketing
of additional products. Altair advanced $560,000 to CURE in this regard.
In
September, 2016, the Company and CURE agreed to terminate the Exclusive License and Distribution Agreement for CURE’s Sildenafil
Products. In its place, the Company and CURE entered into an Exclusive License and Distribution Agreement for a family of sports
related nutraceutical products. The Company has been unable to generate any sales of these products due to a lack of working capital
and the human resources required to introduce the products to market. The Company wrote off its $560,000 investment in the agreement
in the financial statements for the year ended March 31, 2017.
The
Company had previously planned to commence operations in the architectural field and to be responsible for the concept architectural
vision of future private and public buildings as well as municipal organized public areas. This plan was abandoned in the 2015
fiscal year in favor of the business operations described above.
Since
inception (December 20, 2012) through September 30, 2018, the Company has not generated any revenue and has accumulated losses
of $871,112.
In
management’s opinion all adjustments necessary for a fair statement of the results for the interim periods have been made,
and that all adjustments have been made to maintain the books in accordance with GAAP. Furthermore, sufficient disclosures have
been made in order to ensure that the interim financial statements will not be misleading.
NOTE
2 - GOING CONCERN
The
financial statements have been prepared on a going concern basis, which assumes the Company will be able to realize its assets
and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses
since inception resulting in an accumulated deficit of $871,112 as of September 30, 2018 and further losses are anticipated in
the development of its business raising substantial doubt about the Company’s ability to continue as a going concern.
The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or
obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when
they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans
from directors and/or private placement of common stock.
NOTE
3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis
of Presentation
The
accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United
States of America, and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”)
and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present
the financial position, results of operations and cash flows of the Company as of and for the six month periods ending September
30, 2018 and 2017 and year ending March 31, 2018.
Cash
and Cash Equivalents
For
purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity
of three months or less to be cash equivalents.
The
Company's bank accounts are deposited in insured institutions. The funds are insured up to $250,000. At September 30, 2018 the
Company's bank deposits did not exceed the insured amounts.
Basic
and Diluted Income (Loss) Per Share
The
Company computes loss per share in accordance with “ASC-260”, “Earnings per Share” which requires presentation
of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing
net loss available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted
loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share
excludes all potential common shares if their effect is anti-dilutive.
Income
Taxes
The
Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities
are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values
and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities
of a change in tax rates is recognized in income in the period that includes the enactment date.
Fair
Value of Financial Instruments
FASB
ASC 820 "Fair Value Measurements and Disclosures" establishes a three-tier fair value hierarchy, which prioritizes the
inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used
in measuring fair value are observable in the market.
These
tiers include:
Level
1: defined as observable inputs such as quoted prices in active markets;
Level
2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and
Level
3: defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its
own assumptions.
The
carrying amounts of financial assets and liabilities, such as cash and accrued liabilities approximate their fair values because
of the short maturity of these instruments.
Use
of Estimates
The
preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual
results could differ from those estimates.
Reclassifications
Certain
reclassifications have been made to the prior period financial information to conform to the presentation used in the financial
statements for the six month period September 30, 2018.
NOTE
4 – LOANS PAYABLE
During
the fiscal year ended March 31, 2016, the Company obtained a loan from a third party in the amount of $4,175. A further $9,990
was loaned to the Company in the six months ended September 30, 2016. This loan is non-interest bearing, is unsecured and has
no fixed terms of repayment.
NOTE
5 – LOAN ADVANCES
On
April 10, 2018, the Company entered into a non-binding Memorandum of Understanding with Dr. Judy Pham wherein Dr. Pham agreed
to provide up to $100,000 in equity financing to assist with a corporate reorganization including bringing the Company current
in its regulatory filings. On September 26, 2018 Dr. Phan completed her commitment to advance the Company $100,000. On September
27, 2018, the Company entered into a Securities Purchase Agreement with Dr. Judy Pham whereby she acquired 422,222,670 common
shares of the Company for the $100,000 in loan advances.
NOTE
6 – COMMON STOCK
On
August 24, 2018, the Company increased its authorized share capital from 75,000,000 common shares to 2,000,000 common shares with
a par value of $0.001.
The
Company had 47,747,245 common shares issued and outstanding at March 31, 2018.
In
addition, the Company had received share subscriptions and Promissory Note conversion notices for the issuance of an additional
26,762,638 common shares. These shares were issued to the subscribers on April 19, 2018.
On
September 27, 2018, the Company entered into a Securities Purchase Agreement with Dr. Judy Pham whereby she acquired 422,222,670
common shares of the Company for $100,000 in cash advances.
The
Company had 496,732,553 common shares issued and outstanding at September 30, 2018.
NOTE
7 – RELATED PARTY TRANSACTIONS
From
inception through September 29, 2016, the Directors loaned the Company $84,374 net of repayments to pay for incorporation costs,
general and administrative expenses and professional fees and the acquisition of sales and distribution licenses and advances
to Cure Pharmaceutical. On September 29, 2016, this amount was settled through the issuance of a convertible promissory
note. On September 29, 2017, the Director converted $39,373 of principal and $5,062 accrued interest on the promissory note into
4,443,565 shares of common stock. A new non-convertible unsecured, 6% promissory note for the remaining principal balance of $45,000
was issued. The new note matures in eighteen months. On September 29, 2018, the Company made a partial repayment of $15,000 on
this note.
On
September 29, 2016, the Company entered into a consulting agreement with the Company’s sole officer and director for the
provision of management and financial services. This agreement called for a one time payment of $10,000 on signing of the agreement,
and payments of $5,000 per month for six months, terminating on March 30, 2017. In addition, an amount of $5,000 for services
provided in September, 2016 was payable on either the termination of the contract or completion of a minimum $500,000 financing.
As of September 30, 2018, all amounts due to the consultant including $2,500 in late payment fees pursuant to this contract ($47,500)
had been paid.
On
April 10, 2018, the Company agreed to pay the sole officer and director of the company $2,500 per month for a period of 4 months
for the provision of management and financial services. On September 1, 2018, the Company agreed to extend this contract on a
month-to-month basis at the existing rate of $2,500 per month. $12,500 has been paid to September 30, 2018 pursuant to this agreement.
NOTE
8 – SUBSEQUENT EVENTS
In
accordance with ASC 855-10, the Company has analyzed its operations from September 30, 2018 to October 30, 2018 and has determined
that it has no material subsequent events to disclose in these financial statements.
END
OF NOTES TO FINANCIAL STATEMENTS